SCHEDULE: Vanguard Discloses 7.36% Stake in Baxter International

Vanguard Capital Management has reported beneficial ownership of 38,033,907 shares, representing 7.36% of Baxter International Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, has filed a Schedule 13G indicating beneficial ownership of Baxter International Inc. common stock.
• The total number of shares beneficially owned is 38,033,907.
• This holding represents 7.36% of the class of securities.
• Vanguard Capital Management has sole voting power over 4,526,932 shares and sole dispositive power over 38,033,907 shares.
• The filing reflects securities held by Vanguard funds and other managed accounts where Vanguard exercises dispositive and/or voting power.
• The reporting date for this event is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by a major institutional investor and does not contain performance data or strategic announcements.

Positives

• Vanguard's significant stake suggests confidence in Baxter International's long-term prospects.
• The filing indicates a substantial investment by a major institutional investor.

Risks

• The filing does not explicitly mention any risks.
• Potential for increased shareholder activism or influence due to the significant stake.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Baxter International's future performance.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake disclosures by large asset managers like Vanguard often signal a stable or positive outlook on the company's sector, in this case, healthcare and medical devices, which is a highly competitive and regulated industry.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which can be viewed positively for stability and potential long-term value.
• Management: May face increased scrutiny or engagement from Vanguard regarding corporate strategy and governance.
• Employees: Indirect impact through company stability and strategic direction influenced by major shareholders.
• Creditors: Indirect impact through the company's financial stability and operational continuity.

Next Steps

• Vanguard will continue to monitor its investment in Baxter International.
• Baxter International will continue its operations as a medical products company.

Key Dates

Keywords

Baxter International, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management